Millions of Americans are taking GLP-1 medications to manage Type 2 diabetes and obesity. Drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have become increasingly popular and can provide important health benefits. However, a November 9, 2026, announcement from the U.S. Food and Drug Administration (FDA) has raised a new safety concern involving a rare eye condition.

The condition is called Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). It occurs when blood flow to the front portion of the optic nerve is reduced. The resulting damage can cause sudden, painless vision loss, usually in one eye. Unfortunately, the loss of vision can be permanent.

The FDA reviewed 126 clinical trials involving more than 134,000 participants. Its analysis found 6.4 probable NAION cases per 100,000 patient-years among people taking GLP-1 medications, compared with 3.8 cases among those receiving comparison treatments. Although the risk is very small, the FDA considers the potential association important enough to require new warnings on medication labels. These findings do not establish that the medications directly cause NAION.

People with diabetes should pay particular attention

Diabetes itself is a recognized risk factor for NAION. High blood pressure, sleep apnea, kidney disease and smoking can also contribute to the risk.

Another important consideration is diabetic neuropathy. This is a separate complication involving damage to peripheral nerves, commonly affecting the feet and legs and sometimes the hands. Although GLP-1 medications are not established causes of ordinary diabetic peripheral neuropathy, researchers are studying their possible effects on nerve health.

There is also a recognized condition called Treatment-Induced Neuropathy of Diabetes. In some patients with longstanding poor glucose control, a rapid improvement in blood sugar can trigger severe burning pain, tingling and other nerve symptoms. This phenomenon has been associated with several forms of diabetes treatment, not exclusively GLP-1 medications.

The message is not to panic or discontinue prescribed medication independently. Patients should discuss their individual risks with their physicians and continue recommended diabetic eye examinations.

Anyone experiencing sudden, painless vision loss or an abrupt change in vision in one eye should seek immediate medical attention.

Awareness is the goal: Know the symptoms, understand the potential risks, and discuss questions with your healthcare provider. These medications offer significant benefits, but informed patients are better-equipped patients.

In case someone asks, and there’s always one….

• FDA Safety Announcement, November 9, 2026. 
• American Academy of Ophthalmology, November 11, 2026. 
• Review of Treatment-Induced Neuropathy of Diabetes,  PubMed Central (PMC)+1